Baxter International Inc (BAX)
被低估基本面
41
价格
$23.70
市值
$12.14B
第一部分 · 这家公司值多少
概览
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
ICU Medical sells IV solutions, infusion pumps and administration sets to the same US hospital pharmacies and supply contracts that Baxter's Medical Products & Therapies segment depends on.
BD competes head-on with Baxter for hospital infusion contracts with its Alaris smart pumps, IV sets and injectable drug delivery lines.
Stryker is the closest rival to Baxter's Hillrom business for smart hospital beds, patient monitoring and operating-room equipment bought by the same acute-care hospitals.
The German family-owned group offers the same sterile IV fluids, infusion pumps and parenteral nutrition range, and is Baxter's main rival for European hospital tenders.
Fresenius Kabi competes with Baxter both in IV fluids and parenteral nutrition and in specialty injectable generics sold to hospital pharmacies.
资产负债表与流动性
营收
$11.47B
最近12个月（截至2026/6/30）
净利润
$-1.06B
最近12个月（截至2026/6/30）
自由现金流
$332M
股东权益合计
$6.13B
负债合计
$13.95B
流动比率
1.95
利息覆盖率
0.93
债务/EBITDA
0.31
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$64.96
当前价格
$23.70
安全边际
+63.5%
公允价值区间
$42.22 - $87.69
所用估值方法之间的离散区间，并非经过统计校准的置信区间。
估算方法
估值指标
市盈率（P/E）
-
ROE
-15.6%
市净率（P/B）
2.00
P/FCF
36.58
毛利率
30.1%
ROIC
-1.3%
盈利能力雷达图
价值创造（经济护城河）
ROIC
-1.3%
WACC
8.3%
ROIC − WACC
-9.6 pp
ROIC 低于资本成本：公司每投入一美元都在毁灭价值。
基本面分析标准
通过（10）
- Gross Margin 30.1%
- P/B Ratio 2.00
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Earnings Surprise avg 15.7%
- Share Dilution 0.1%
- Piotroski F-Score 6/9
未通过（13）
- EPS shows upward trend
- Price CAGR -6.03%
- ROIC -1.3%
- P/FCF 36.58
- Operating Margin -2.4%
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE -16.6%
- Revenue Growth 5Y -0.8%
- Analyst Consensus 25% Buy
- Net Margin Trend -9.3% vs -1.4%
不可用（4）
- Dividend Payout NaN%
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-评分
信号混杂：部分领域需关注
盈利质量
低质量：需深入审查会计处理
股权稀释
股份数量稳定
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Andrew P. Hider | CEO, President, Interim Group President of Medical Products & Therapies and Director | 48 |
| Mr. David S. Rosenbloom | Executive VP & General Counsel | 65 |
| Ms. Maria Soriano | Group President of Infusion Therapies & Platforms | - |
| Ms. Anita A. Zielinski | Interim CFO, Senior VP, Chief Accounting Officer & Controller | 52 |
| Mr. Charles Patel | Senior VP & Chief Information Officer | 55 |
| Mr. Kevin Moran | Vice President & Head of Investor Relations | - |
| Ms. Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation | - |
| Ms. Cynthia Carlisle | Executive VP & Chief Human Resources Officer | 50 |
| Mr. James W. Borzi | Executive VP & Chief Supply Chain Officer | 62 |
| Mr. Steven P. Wallace | President of Advanced Surgery & Commercial Excellence | 45 |
审计风险
3
董事会风险
2
薪酬风险
9
股东权利风险
2
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for BAX, sourced from Markets Gazette.